Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:33 AM
Ignite Modification Date:
2025-12-26 @ 10:33 AM
NCT ID:
NCT02938728
Eligibility Criteria:
Inclusion Criteria:
* Unresectable stage III or stage IV melanoma
* Eligible to anti-PD1 therapy alone or combined to anti CTLA4.
* Informed consent
* Age \>18 year
Exclusion Criteria:
* Persistent toxicity \> grade 2 (NCIC-CTCAE version 4) related to 1 regimen before switching to the other
* Ocular melanoma
* Active, known or suspected autoimmune disease which could be significantly worsened by immunotherapies; patients with vitiligo, type I diabetes mellitus, hypothyroidism, psoriasis non requiring systemic treatment are permitted to enroll.
* HIV infection
* Active Interstitial lung disease or pneumonitis
* Contra-indication for tumor biopsy
* No health care insurance
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02938728
Study Brief:
Protocol Section:
NCT02938728